The toxicokinetics of the food and feed contaminant Fumonisin B (FB) are characterized by low oral absorption and rapid plasma elimination. For these reasons, FB is not considered to accumulate in animals. However, recent studies in chicken and turkey showed that, in these species, the hepatic half-elimination time of fumonisin B1 (FB1) was several days, suggesting that FB1 may accumulate in the body. For the present study, 21-day-old chickens received a non-toxic dose of around 20 mg FB1 + FB2/kg of feed to investigate whether FB can accumulate in the body over time. Measurements taken after four and nine days of exposure revealed increased concentrations of sphinganine (Sa) and sphingosine (So) over time in the liver, but no sign of toxicity and no effect on performances were observed at this level of FB in feed. Measurements of FB in tissues showed that FB1 accumulated in chicken livers from four to nine days, with concentrations of 20.3 and 32.1 ng FB1/g observed, respectively, at these two exposure periods. Fumonisin B2 (FB2) also accumulated in the liver, from 0.79 ng/g at four days to 1.38 ng/g at nine days. Although the concentrations of FB found in the muscles was very low, an accumulation of FB1 over time was observed in this tissue, with concentrations of 0.036 and 0.072 ng FB1/g being measured after four and nine days of exposure, respectively. Feeding algo-clay to the chickens reduced the accumulation of FB1 in the liver and muscle by , approximately 40 and 50% on day nine, respectively. By contrast, only a weak non-significant effect was observed on day four. The decrease in the concentration of FB observed in tissues of chickens fed FB plus algo-clay on day nine was accompanied by a decrease in Sa and So contents in the liver compared to the levels of Sa and So measured in chickens fed FB alone. FB1 in the liver and Sa or So contents were correlated in liver tissue, confirming that both FB1 and Sa are suitable biomarkers of FB exposure in chickens. Further studies are necessary to determine whether FB can accumulate at higher levels in chicken tissues with an increase in the time of exposure and in the age of the animals.

Sows were fed naturally contaminated diets containing: (i) 100 ppb zearalenone (ZEN) one week before farrowing and during the lactation period (at 26 days), (ii) 100 ppb ZEN one week before farrowing and 300 ppb ZEN during the lactation period, or (iii) 300 ppb ZEN one week before farrowing and during the lactation period. All diets contained 250 ppb deoxynivalenol (DON). The highest levels of ZEN, α-ZEL, or β-ZEL were observed in the serum of sows fed 300 ppb ZEN before farrowing and during lactation. However, only α-ZEL was significantly increased in the colostrum and milk of these sows. Sows fed the 300 ppb ZEN during the complete trial presented a significant decrease in backfat thickness before farrowing. This effect was accompanied by a decrease in serum leptin levels. These sows also presented a decrease in estradiol levels and this effect was observed in their piglets exposed during lactation, which presented increased glucagon-like peptide 1, but no changes in serum levels of ZEN, α-ZEL, or β-ZEL. Although all sows were fed the same levels of DON, the serum levels of DON and de-epoxy-DON were increased only in the serum of piglets from the sows fed a diet with the highest ZEN levels during the whole experimental period. Moreover, these piglets presented gut inflammation, as indicated by significantly increased calprotectin levels in their serum.

The mycotoxin deoxynivalenol (DON) is frequently present in cereals at low levels, resulting in its occurrence in food and feed. DON has been proven to alter the immune response and induce inflammation in all species, with pigs exhibiting heightened sensitivity and exposure. However, no study has yet evaluated the effects of exposure to DON at the recommended levels in pig feed. In two separate trials, piglets were subjected to control feed or feed contaminated with a low level of purified DON (0.83 mg/kg feed in trial 1 and 0.85 mg/kg feed in trial 2) for either three weeks (trial 1) or two weeks (trial 2). Additionally, a group of animals exposed to 2.85 mg/kg feed of DON was included as a positive control in Trial 1. The impact of DON on porcine tissues (intestine, liver, and spleen) was evaluated through histological and qPCR analyses of immune-related genes. Additionally, biochemical analyses and acute-phase proteins were examined in plasma samples. Lesions were identified in the intestine (jejunum and ileum), the liver, and the spleen of pigs receiving diets contaminated with low and high concentrations of DON. The low level of DON also resulted in impaired expression of genes associated with intestinal barrier integrity, intestinal immune responses, and liver function. In conclusion, the results of the two trials demonstrate the impact of DON exposure even at doses below the recommended level of 0.9 mg/kg feed set by the European Union. This suggests that the current recommended level should be reconsidered to ensure the optimal health and well-being of pigs.

The aims of this study were (i) to determine the effect of an algoclay-based decontaminant on the oral availability of three mycotoxins (deoxynivalenol; DON, ochratoxin A; OTA, and aflatoxin B₁; AFB₁) using an oral bolus model and (ii) to determine the effect of this decontaminant on the performance, intestinal morphology, liver oxidative stress, and metabolism, in broiler chickens fed a diet naturally contaminated with DON. In experiment 1, sixteen 27-day-old male chickens (approximately 1.6 kg body weight; BW) were fasted for 12 h and then given a bolus containing either the mycotoxins (0.5 mg DON/kg BW, 0.25 mg OTA/kg BW, and 2.0 mg AFB₁/kg BW) alone (n = 8) or combined with the decontaminant (2.5 g decontaminant/kg feed; circa 240 mg/kg BW) (n = 8). Blood samples were taken between 0 h (before bolus administration) and 24 h post-administration for DON-3-sulphate, OTA, and AFB₁ quantification in plasma. The algoclay decontaminant decreased the relative oral bioavailability of DON (39.9%), OTA (44.3%), and AFB₁ (64.1%). In experiment 2, one-day-old male Ross broilers (n = 600) were divided into three treatments with ten replicates. Each replicate was a pen with 20 birds. The broiler chickens were fed a control diet with negligible levels of DON (0.19–0.25 mg/kg) or diets naturally contaminated with moderate levels of DON (2.60–2.91 mg/kg), either supplemented or not with an algoclay-based decontaminant (2 g/kg diet). Jejunum villus damage was observed on day 28, followed by villus shortening on d37 in broiler chickens fed the DON-contaminated diet. This negative effect was not observed when the DON-contaminated diet was supplemented with the algoclay-based decontaminant. On d37, the mRNA expression of glutathione synthetase was significantly increased in the liver of broiler chickens fed the DON-contaminated diet. However, its expression was similar to the control when the birds were fed the DON-contaminated diet supplemented with the algoclay-based decontaminant. In conclusion, the algoclay-based decontaminant reduced the systemic exposure of broiler chickens to DON, OTA, and AFB₁ in a single oral bolus model. This can be attributed to the binding of the mycotoxins in the gastrointestinal tract. Moreover, dietary contamination with DON at levels between 2.69 and 2.91 mg/kg did not impair production performance but had a negative impact on broiler chicken intestinal morphology and the liver redox system. When the algoclay-based decontaminant was added to the diet, the harm caused by DON was no longer observed. This correlates with the results obtained in the toxicokinetic assay and can be attributed to a decreased absorption of DON.

This study investigated biomarkers of fumonisin exposure in pigs fed diets contaminated with fumonisins at the European Union’s maximum recommended level. Pigs were assigned to either a fumonisin (FB) diet or a fumonisin plus AlgoClay (FB + AC) diet for durations of 4, 9, and 14 days. At 14 days, the plasma Sa1P:So1P ratio increased in pigs fed the FB diet, while the Sa:So ratio remained unchanged. In the liver, FB1 was detected at four days of exposure, with the concentration tending to increase through day 14. The Sa:So and C22-24:C16 ratios of 18:1-, 18:2-, and m18:1-ceramides were elevated at 9 and 14 days, respectively. In the kidneys, FB1 was only detectable at 14 days, and the Sa:So and C22-24:C16 ratios of 18:1-ceramides were increased. In both the liver and kidneys, the increase in the C22-24:C16 ratio was attributed to a reduction of C16 ceramides. In the lungs, no FB1 was detected; however, the Sa:So and Sa1P:So1P ratios increased, and C16 ceramide concentrations decreased at 14 days. Feeding the pigs the FB + AC diet resulted in a reduction of the FB1 tissue-to-feed ratio in the liver and kidneys but did not affect the Sa:So or Sa1P:So1P ratios. Interestingly, the decreases in C16 ceramides observed in the FB diet group were no longer detectable in the FB + AC group. Overall, these findings highlight the complexity of the relationship between FB1 tissue concentrations and sphingolipid changes, suggesting that a comprehensive analysis of multiple biomarkers is required to fully understand fumonisin’s effects.